Overview

LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Based on network pharmacology, Liuweiluobi Granule was screened to treat diabetes peripheral neuropathy with deficiency of the spleen and kidney and stasis-heat syndrome.In the preliminary animal experiment, it suggested that this granule had a significant protective effect on the peripheral motor nerves of diabetic peripheral neuropathy and the effect of anti-inflammation, and the prescription did not induce the death of zebrafish at a concentration of 1000 ug/mL, without any obvious toxicity. This study aims to evaluate the efficacy of Liuweiluobi Granule in improving neurotransmission function in patients with diabetic peripheral neuropathy through a pilot, randomized controlled study.
Phase:
Early Phase 1
Details
Lead Sponsor:
China Academy of Chinese Medical Sciences